Stock listing

LSE:0A8I Genprex, Inc. Share Price

UK listing (LSE) of Genprex, Inc. · home listing NASDAQ:GNPX

Follow Genprex, Inc. into a list and get an email when it puts out news.

Share price · LSE:0A8I

$1.92 USD +0.11 (+6.1%)

Close on Oct 27, 2026

Day range
$1.75 – $1.92 USDOct 27, 2026
Volume
124 sharesOct 27, 2026
Genprex, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GNPX · Home$2.24 USD+0.20 (+9.8%)164,563$2.02$2.27$2.02$2.04Close on Oct 30, 2026
LSE:0A8I$1.92 USD+0.11 (+6.1%)124$1.89$1.92$1.75$1.81Close on Oct 27, 2026
Ticker
LSE:0A8I
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
USD

What changed lately

Latest news

Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting

Oct 28, 2026

Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging

Oct 21, 2026

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 8, 2026

Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program

Sep 1, 2026

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Aug 18, 2026

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Aug 3, 2026

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Jun 22, 2026

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

May 26, 2026

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Apr 30, 2026

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Apr 28, 2026

All Genprex, Inc. news

Decks

Genprex, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 126 in all · newest Oct 28, 2026 · oldest 2019
Decks
26 decks · latest Jul 14, 2026

Where Genprex, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GNPX · Home listingNASDAQUnited StatesUSD
BOATS:GNPXBOATSUnited StatesUSD
Frankfurt:2DEFrankfurtGermanyEUR
LSE:0A8I · This pageLSEUnited KingdomUSD
gettex:2DEgettexGermanyEUR
Munich:2DEMunichGermanyEUR

Log in to ask 6ix AI your own questions about Genprex, Inc.